These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 11025866)

  • 41. The role of glycoprotein IIb/IIIa platelet inhibition in percutaneous coronary intervention in the stent era.
    Adelman AG; Caramori PR; Cohen EA; Chisholm RJ; Côté G; Ducas J; O'Neill BJ; Tcheng JE
    Can J Cardiol; 1998 Aug; 14(8):1057-66. PubMed ID: 9738165
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial).
    Kandzari DE; Tcheng JE; Cohen DJ; Bakhai A; Grines CL; Cox DA; Effron M; Stuckey T; Griffin JJ; Turco M; Carroll JD; Fahy M; Mehran R; Stone GW;
    Am J Cardiol; 2003 Oct; 92(7):779-84. PubMed ID: 14516875
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The benefit of abciximab in percutaneous coronary revascularization is not device-specific.
    Bhatt DL; Lincoff AM; Califf RM; Simoons ML; Tcheng JE; Brener SJ; Wolski KE; Topol EJ
    Am J Cardiol; 2000 May; 85(9):1060-4. PubMed ID: 10781752
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trials.
    de Queiroz Fernandes Araújo JO; Veloso HH; Braga De Paiva JM; Filho MW; Vincenzo De Paola AA
    Am Heart J; 2004 Dec; 148(6):937-43. PubMed ID: 15632875
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial.
    van den Brand M; Laarman GJ; Steg PG; De Scheerder I; Heyndrickx G; Beatt K; Kootstra J; Simoons ML
    Eur Heart J; 1999 Nov; 20(21):1572-8. PubMed ID: 10529325
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials.
    Kandzari DE; Hasselblad V; Tcheng JE; Stone GW; Califf RM; Kastrati A; Neumann FJ; Brener SJ; Montalescot G; Kong DF; Harrington RA
    Am Heart J; 2004 Mar; 147(3):457-62. PubMed ID: 14999194
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Abciximab reduces mortality in diabetics following percutaneous coronary intervention.
    Bhatt DL; Marso SP; Lincoff AM; Wolski KE; Ellis SG; Topol EJ
    J Am Coll Cardiol; 2000 Mar; 35(4):922-8. PubMed ID: 10732889
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intracoronary compared to intravenous abciximab in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention reduces mortality, target vessel revascularization and reinfarction after 1 year.
    Iversen AZ; Galatius S; Abildgaard U; Galloe A; Hansen PR; Pedersen S; Engstroem T; Jensen JS
    Cardiology; 2011; 120(1):43-9. PubMed ID: 22122887
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade.
    Kereiakes DJ; Berkowitz SD; Lincoff AM; Tcheng JE; Wolski K; Achenbach R; Melsheimer R; Anderson K; Califf RM; Topol EJ
    Am Heart J; 2000 Jul; 140(1):74-80. PubMed ID: 10874266
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization: Pooled analysis from EPIC, EPILOG, and EPISTENT.
    Cho L; Bhatt DL; Wolski K; Lincoff M; Topol EJ; Moliterno DJ
    Am Heart J; 2001 Apr; 141(4):599-602. PubMed ID: 11275926
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention.
    Akkerhuis KM; Deckers JW; Lincoff AM; Tcheng JE; Boersma E; Anderson K; Balog C; Califf RM; Topol EJ; Simoons ML
    JAMA; 2001 Jul; 286(1):78-82. PubMed ID: 11434830
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Abciximab offers greater benefits to insulin-dependent diabetic patients undergoing coronary stent implantation.
    López-Mínguez JR; Nogales JM; González R; Palanco C; Doncel J; Vaello A; Giménez F; Morales A; Alonso R; Merchán A
    Cardiovasc Revasc Med; 2007; 8(3):175-82. PubMed ID: 17765647
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term clinical benefits of a platelet glycoprotein IIb/IIIa receptor blocker, abciximab (ReoPro), in high-risk diabetic patients undergoing percutaneous coronary intervention.
    Sim DS; Jeong MH; Kim W; Rhew JY; Yum JH; Kim JH; Cho JG; Ahn YK; Park JC; Ahn BH; Kim SH; Kang JC
    Korean J Intern Med; 2003 Sep; 18(3):129-37. PubMed ID: 14619381
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of abciximab on coronary restenosis in diabetic patients undergoing elective paclitaxel-eluting stent implantation. A prospective, randomized, placebo-controlled study.
    De Luca L; Sardella G; De Persio G; Petrolini A; Fedele F
    Acute Card Care; 2008; 10(2):93-9. PubMed ID: 18568571
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications.
    Narins CR; Miller DP; Califf RM; Topol EJ
    J Am Coll Cardiol; 1999 Mar; 33(3):647-53. PubMed ID: 10080464
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of the role of abciximab (Reopro) as a rescue agent during percutaneous coronary interventions: in-hospital and six-month outcomes.
    Velianou JL; Strauss BH; Kreatsoulas C; Pericak D; Natarajan MK
    Catheter Cardiovasc Interv; 2000 Oct; 51(2):138-44. PubMed ID: 11025564
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing.
    Lincoff AM; LeNarz LA; Despotis GJ; Smith PK; Booth JE; Raymond RE; Sapp SK; Cabot CF; Tcheng JE; Califf RM; Effron MB; Topol EJ
    Ann Thorac Surg; 2000 Aug; 70(2):516-26. PubMed ID: 10969673
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A risk-benefit assessment of abciximab in angioplasty.
    Kleiman NS
    Drug Saf; 1999 Jan; 20(1):43-57. PubMed ID: 9935276
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Glycoprotein IIb/IIIa inhibition in early intent-to-stent treatment of acute coronary syndromes: EPISTENT, ADMIRAL, CADILLAC, and TARGET.
    Moliterno DJ; Chan AW
    J Am Coll Cardiol; 2003 Feb; 41(4 Suppl S):49S-54S. PubMed ID: 12644341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.